2021 Advanced Heart Failure Symposium

Welcome/Opening Remarks

Joe Harmon Memorial Lecture: Recognizing and Referring Patients for Advanced Heart Failure Therapies

Objectives

• 1. The provider will be able to use both objective and subjective data when assessing their patient, in order to discern when someone should be referred for Adv HF Evaluation. 2. The care providers will know what testing to order to help determine what stage of HF their patient is in and be able to interrogate the results. 3. The participant will be able to recognize the options available to patients who have stage D HF or are nearing that point.

Cardiorenal Syndrome From the Nephrologist’s View Point

Objectives

• 1. The Provider will understand the factors/lab testing that signify Cardio-renal syndrome. 2. The Provider will understand the treatments and methods to try to counteract Cardio-renal syndrome.

Basic Hemodynamics

Objectives

• 1. The participant will be able to recognize the normal pressure ranges and blood flow in the heart. 2. The participant will be able to use hemodynamics to determine the appropriate therapy for a heart failure patient.

PHTN (RV failure)

Objectives

• 1. The participant will be able to recognize the WHO classes of PHTN. 2. The participant will be able to recognize the hemodynamics that discern PAH from PVH.

Ambulatory Advanced Heart Failure

Objectives

• 1. The participate will describe a step-by-step approach to diuretic escalation in a patient with advanced heart failure who demonstrates fluid retention and diuretic resistance. 2. The participate will be able to list 3 or more non-pharmacologic interventions for the management of patients with advanced heart failure. 3. The participant will identify high risk parameters which would prompt a referral to hospice in a patient with advanced heart failure, ineligible for surgical interventions.

Panel with Difficult Cases

Objectives

• 1. Provide examples of patients with end-stage heart failure warranting evaluation for advanced therapies. 2. Discuss relative versus absolute contraindications for LVAD therapy and heart transplant through these examples.

Industry Presentation Sponsored by Abbott Utilizing CardioMEMS™ HF System to Trigger Advanced Heart Failure Evaluation

Structural Heart – Non-Surgical Interventions

Objectives

• 1. The participant will be able to identify the appropriate candidate for Mitral Clip, TAVR or Tricuspid clip, along with the studies involved in making the decision. 2. The participant will recognize the care needed following a structural heart procedure.

Workup for Advanced Therapy

Objectives

• 1. Discuss components and diagnostic work-up for advanced heart failure therapies 2. Review the key healthcare providers and their roles in evaluating patients for advanced HF therapies

Less Typical Cardomyopathies

Objectives

• 1. Discuss evaluation and management of infiltrative and genetic cardiomyopathies 2. Describe evaluation and management strategies for hypertrophic cardiomyopathy

Cardiac Echo Images, Cases – Less Typical /Peri-Partum/MRIs

Objectives

• 1. Identify the major structures (chambers and valves) in ultrasound images of the heart. 2. Recognize and describe the standard views of transthoracic cardiac ultrasound and identify the utility of each view. 3. Review the role of echocardiography in the diagnosis and management of heart failure patients (systolic and diastolic dysfunction). 4. Discuss clinical situations that outline the use of this diagnostic study. 5. Review the most recent ACCF/AHA & HFSA Heart Failure Guidelines for the use of echocardiography in heart failure patients

Covid-19 and Cardiomyopathy

Objectives

• 1. The participant will describe methods for diagnosing COVID-19 associated myocarditis. 2. The participant will list at least 2 interventions for the management of COVID-19 associated myocarditis. 3. The participant will explain the relationship between m-RNA COVID-19 vaccines and myocarditis

New FDA Approved Thearpies

Objectives

• 1. Discuss the evidence for the use of SGLT2 inhibitors in the management of heart failure 2. Review the clinical evidence for the use of soluble guanylate cyclase stimulator in the management of heart failure 3. Describe therapies on the horizon in clinical trial for heart failure

Industry Presentation Sponsored by AstraZeneca A Treatment Option for Patients with Heart Failure with Reduced Ejection Fraction